Cardiovascular disease, cardiometabolic syndromes, and coronary artery disease are the primary causes of morbidity and mortality worldwide. It is estimated that the annual number of human deaths related to cardiovascular disease is over 17.5 million worldwide, of which 80% of these deaths are due to strokes and heart attacks, and over 75% of these incidents occur in developing nations. A long-running World Health Organization project monitored coronary heart disease across 37 populations in more than 20 countries on four continents for more than 10 years. A diagnosis of MI means that a patient’s heart muscle rapidly loses its blood supply. Without immediate treatment of the blockage, the event will lead to permanent damage in the affected areas of the heart. Ischemic heart disease, also called coronary artery disease, is usually caused by plaque narrowing the coronary arteries, and a heart attack most often happens when a blood clot forms on that plaque, an event called coronary thrombosis.[1]
What Causes Heart Attacks?
The most common cause of MI (Myocardial Infarction) is thrombosis, a blood clot that forms in a coronary artery, and the heart muscle damage left by a heart attack is a leading cause of congestive heart failure. These clots usually come from inside one of the branches of the coronary artery. The clot restricts vital blood flow to the heart. This type of blood clotting typically doesn’t occur in healthy arteries unless there are preexisting atheromas within the arterial wall. Atheromas or plaque
If a crack develops in the outer shell of the atherosclerotic plaque, the event is known as plaque rupture. This rupture exposes the inner core to circulating blood, triggering the blood-clotting mechanism and resulting in a blood clot. A buildup of plaque is usually the underlying issue that leads to the death of heart muscle cells and a heart attack. It’s worth noting that atheromas can develop in any part of the coronary arteries. If treated early, emergency angioplasty or thrombolytic (clot-dissolving) medications can restore blood flow, while anticoagulant and antiplatelet medications help stop the clot from growing. Anyone with symptoms of a heart attack should call emergency services right away.
Other causes of blocked arteries and heart attack include:
- Chronic inflammation of the coronary arteries
- Complications from open-heart surgeries
- Reduce infarct size & reduction in scarring of heart muscles caused by cardiogenic shock
- A clot forms elsewhere and then travels to the coronary artery causing blockage
- Drug abuse can also cause a coronary artery to go into spasm
- Failed surgeries leading to the death of cardiac muscle
Heart Attack vs. Cardiac Arrest: Understanding the Differences
While many people use the terms “heart attack” and “cardiac arrest” interchangeably, they are distinctly different cardiac events with unique characteristics, causes, and treatment approaches. A heart attack, medically known as a myocardial infarction, occurs when blood flow to a part of the heart muscle is blocked, typically by a blood clot. This blockage prevents oxygen-rich blood from reaching the affected area of the heart, causing tissue damage or death. Think of it as a “circulation” problem – like a clogged pipe in your heart’s plumbing system. During a heart attack, the heart usually continues beating, and the person typically remains conscious but experiences symptoms such as chest pain, shortness of breath, cold sweats, and pain radiating to the arms, neck, or jaw.
In contrast, cardiac arrest is an “electrical” problem where the heart suddenly stops beating altogether due to a malfunction in its electrical system. This causes an immediate cessation of blood flow throughout the body, leading to loss of consciousness and pulse within seconds. Without immediate intervention, cardiac arrest can result in death within minutes. While a heart attack can sometimes trigger cardiac arrest, they are separate conditions requiring different emergency responses. Heart attack victims usually remain conscious and require immediate transportation to a hospital for treatments like clot-busting medications or angioplasty. Cardiac arrest victims, however, need immediate CPR and defibrillation to restart the heart’s electrical system.
Survival rates and outcomes also differ significantly. Heart attacks, when treated promptly, often have better survival rates and recovery possibilities. In contrast, cardiac arrest has a lower survival rate due to the complete stoppage of heart function and the critical importance of immediate intervention. Understanding these differences is crucial for medical professionals and the general public, as recognizing the specific emergency can lead to more appropriate and timely responses, potentially saving lives.
Symptoms of a Pending Heart Attack – Heart MI
The body displays several warnings leading up to a heart attack. The most common symptom is severe chest pain, but pain can also travel to the jaw area, along with the right or left arm (or both). Patients also report heavy sweating and feeling faint or sick. The pain experienced by patients is very similar to angina, but it’s usually much more severe and persists for longer. While angina usually disappears after a few minutes, pain from a heart attack lasts anywhere from 10 minutes to several hours. Heart attack symptoms, such as chest pain, should be taken seriously and not ignored.[3]
Inside the heart
A cutaway view of the chambers and major vessels.
A small/minor heart attack can occur with or without pain (relatively mild), leading the victim to think it’s just a lack of oxygen or heartburn. Significant or severe cardiac events can cause instant collapse, brain strokes, heart failure, dangerous heart rhythms, and sudden death. Many people recover without further complications if addressed early after the initial incident.
For some patients, an emergency angioplasty is required as an alternative to a ‘clot-busting’ medication. An angioplasty procedure uses a catheter with a balloon at the tip. The wire is advanced into the large artery in the patient’s arm or groin. The wire then travels up to the heart and into the blocked coronary artery under X-ray guidance. When it reaches the site of the blockage, the balloon is inflated to widen the artery and press the plaque against the artery wall, and a stent is usually placed to help keep the artery open.[4]
Dangers of Silent Ischemia
Diagnosis of Acute Myocardial Infarction
Severe chest pain is a symptom, but not the only indicator, of impending damage to cardiac function. Proper clinical diagnosis of heart attacks requires physical examinations and diagnostic tests performed by a trained cardiologist. Commonly used tests for MI include Electrocardiogram (ECG), Echocardiogram, angiography, nuclear stress testing (cardiac stress tests), CT coronary angiography, Cardiac catheterization, and blood tests. The Heart Regeneration Center also offers genetic screening to look for mutations in genes that might lead to heart disease or heart attacks, using the following genetic markers:
TAZ,CAV3,CRYAB,CSRP3,TNNC1, TNNI3, JUP,DOLK, DES,VCL,MYL3, ACTC1, ACTN2,GAA, GLA,RBM20, RYR2, SCN5A, SGCD,TCAP, TMEM43, LAMP2,PRKAG2, RAF1,EYA4,ABCC9,DSC2 LMNA,MYBPC3,PKP2,PLN,DSG2, DSP,AGL,BAG3,TNNT2, TPM1,FHL1,EMD, MYH7, MYL2,HCN4,FKRP, FKTN, FLNC, TTN, TTR, SLC22A5,CTNNA3,LDB3,CACNA1C, ANKRD1, PDLIM3 and DMD.
Proactive Genetic screenings are recommended for family members of patients who may have had sudden cardiac events in the past. Early intervention is vital in managing any condition, so direct relatives can use noninvasive DNA tests to determine whether they carry gene mutations. The Regeneration Center does not offer gene therapies to treat congenital heart disease. Several clinical trials are currently underway to potentially develop a cure for genetic heart diseases. To reduce the risk of heart attacks, maintain a healthy weight, make dietary changes, stop smoking, and engage in regular exercise. A healthy weight and regular exercise can also help protect the joints from osteoarthritis.
Stem Cells for Coronary Thrombosis
Cardiac Stem cell treatments (CSCs) are the only safe and non-surgical method to repair heart attack damage and improve ventricular muscle function after ischemic injury. Recent stem cell research has shown that cardiac stem cell repair works effectively by engrafting new cardiomyocytes, endothelial cells, progenitor cells, and cardiac pacemaker cells to the infarct zone (damaged area), which helps to replace the (necrotic) dead myocardial tissue, induce arteriogenesis, and help establish new blood microvessels through the process known as angiogenesis. Another issue that can occur due to heart attacks is Atrial fibrillation (AFib) or irregular heartbeats. AFib rarely causes a heart attack directly, while a heart attack can lead to atrial fibrillation (AF). After an acute myocardial infarction, reduced blood flow and strain on the heart can damage atrial tissue and cause fibrosis, which can lead to arrhythmias such as AF. If the heart pumps less effectively due to damage/fibrosis, it leads to a higher risk of strokes, periods of rapid heart rates, angina & atrial fibrillation.
Cardiac Myopathy – Angina vs. Heart Attack
The Regen Centre protocol for heart attacks uses cultured UC-MSC+ cells, which are mesenchymal stromal cells being studied for a possible supportive role in heart muscle and blood vessel repair. As with stem cell treatment for dcm, treatments for Congestive Heart Failure, and coronary heart disease, this approach is investigational: it has not been shown to generate large numbers of new heart muscle cells, lower the risk of further cardiovascular events, restore lung function, or prevent lung diseases such as COPD or IPF, liver cirrhosis, or kidney failure.
1 Year After Stem Cell Treatment for Heart
The heart regeneration protocol for the treatment of damaged myocardium also focuses on generating endothelial and vascular smooth muscle cells to increase the blood supply required for myocardial repair and to promote paracrine effects. Cell development improves Paracrine signaling (cell-cell communication), which is critical in helping induce regenerative changes in surrounding progenitor cells and can be observed after cell infusions in (bFGF) fibroblast growth factors, (PDGF) platelet-derived growth factors, interleukin-1b & TGF-b and plays a vital immunomodulatory role in repairing heart tissue after heart attacks.[5]
Coronary Arteriogenesis & Cardiopoietic Stem Cell Therapy
Delivery of adult cardiac myocytes to the damaged myocardium can be achieved using both surgical and noninvasive approaches, depending on the patient’s condition and needs. Minimally invasive means include catheter-based cell delivery, intracoronary infusion, and trans-endocardial injection; these are performed through a catheter without open heart surgery, although they carry procedural risks such as bleeding, vessel injury, or irregular heart rhythms. Through proper cell culturing, Cell Isolation, G-CSF, and cell differentiation techniques, non-invasive, non-surgical cell delivery can be achieved via intravenous and intramuscular cell infusions to circumvent dead heart muscle. Learn more about the basics of stem cells.[6]
Cell sources and terminology
A guide to the source labels used in the laboratory illustration.
- Adipose tissue
ADSC
- Bone marrow
BM-MSC
- Peripheral blood
PB-MSC
- Placental tissue
P-MSC
- Umbilical cord
UC-MSC
- UC-MSC+
The Regeneration Center’s terminology used in this article.
Heart Regeneration Therapy Guidelines for 2026
The number of Cardiopoietic Stem cells needed will vary based on patient needs. Severe cases with multiple comorbidities may require a multiple-stage delivery using transvascular injections with direct injection into the ventricular walls. Cardiopoietic stem cells represent a promising avenue for cardiac regeneration, as they are specifically directed to form heart tissue. These cells are generated by reprogramming mesenchymal stem cells into a lineage committed to cardiac repair, using a defined combination of growth factors. Growth factors, such as transforming growth factor-beta (TGF-β), bone morphogenetic proteins (BMPs), and vascular endothelial growth factor (VEGF), play a pivotal role in this process by promoting the differentiation, survival, and function of these stem cells within the damaged cardiac tissue. The synergy between cardiopoietic stem cells and growth factors enhances regenerative potential, aiming to restore cardiac function and improve clinical outcomes in patients with heart disease.
Repair Damaged Heart Muscles w/ Stem Cells
The ultimate goal of our cellular transplantation after heart attacks is first to stop the progression of the disease and the regeneration of any lost heart muscle. The overall success of any heart attack or heart valve regeneration treatment is measured 3-5 months after therapy using updated tests. The total number of cells required for maximal efficacy depends on several factors, including the patient’s current health status and the age of the injury. Please note that cardiac regeneration therapy after heart attacks is not a 1-3 day treatment and requires multiple stages over two weeks. Due to varying severity, our medical team must review the patient’s current and historical condition before acceptance. For eligible patients, a complete treatment plan shall be provided, including details of the protocol and the fixed medical costs associated with treating heart attacks with stem cells. To begin a medical evaluation, please prepare recent test results from an EKG, tilt table test, heart CT scan, Echocardiogram, or SPECT exam (Single-photon emission computed tomography) and contact us today.
Physical Rehabilitation Post-MI Therapy: Cardiac rehabilitation is a recommended part of recovery after a heart attack, and patients should continue it with their own cardiology team. Rehabilitation during the stay at our center can be arranged depending on the patient’s time constraints. Complete rehabilitation and nursing care can be provided for 2-6 hours per day, up to 5 days per week. Medical visas and accommodations for the patient and family/friends at an extended-stay hotel can also be included upon request.
Published Clinical Citations
[1] ^ Srimahachota, Suphot, Smonporn Boonyaratavej, Pairoj Rerkpattanapipat, Somjai Wangsupachart, Monravee Tumkosit, Udomsak Bunworasate, Thayapong Na Nakorn, et al. 2011. Intra-coronary bone marrow mononuclear cell transplantation in patients with ST-elevation myocardial infarction: a randomized controlled study. Journal of the Medical Association of Thailand Chotmaihet thangphaet, no. 6. https://www.ncbi.nlm.nih.gov/pubmed/21696072
[2] ^ Hou, Jingying, Lingyun Wang, Jieyu Jiang, Changqing Zhou, Tianzhu Guo, Shaoxin Zheng, and Tong Wang. 2013. Cardiac stem cells and their roles in MI. Stem cell reviews and reports, no. 3. doi:10.1007/s12015-012-9421-4. https://www.ncbi.nlm.nih.gov/pubmed/23238707
[3] ^ Limsuwan, Alisa, Pavit Pienvichit, Thosaphol Limpijankit, Pongsak Khowsathit, Suradej Hongeng, Ratanaporn Pornkul, Suvipaporn Siripornpitak, and Sarana Boonbaichaiyapruk. 2010. Transcoronary bone marrow-derived progenitor cells in a child with myocardial infarction: first pediatric experience. Thailand Clinical cardiology, no. 8. doi:10.1002/clc.20463. https://www.ncbi.nlm.nih.gov/pubmed/20632394
[4] ^ Carvalho, Edmund, Paul Verma, Kerry Hourigan, and Rinti Banerjee. 2015. Myocardial infarction: stem cell transplantation for cardiac regeneration. Regenerative medicine, no. 8 (November 13). doi:10.2217/rme.15.63. https://www.ncbi.nlm.nih.gov/pubmed/26563414
[5] ^ Boonbaichaiyapruck, Sarana, Pavit Pienvichit, Thosapol Limpijarnkij, Pairoj Rerkpattanapipat, Apichai Pongpatananurak, Ratchanee Saelee, Artit Ungkanont, and Suradej Hongeng. 2010. Transcoronary infusion of bone marrow-derived multipotent stem cells to preserve left ventricular geometry and function after myocardial infarction. Clinical cardiology, no. 7. doi:10.1002/clc.20545. https://www.ncbi.nlm.nih.gov/pubmed/20552656
[6] ^ Nartprayut, Kuneerat, Yaowalak U-Pratya, Pakpoom Kheolamai, Sirikul Manochantr, Methichit Chayosumrit, Surapol Issaragrisil, and Aungkura Supokawej. 2013. Cardiomyocyte differentiation of perinatally‑derived mesenchymal stem cells. Molecular medicine reports Thailand, no. 5 (March 4). doi:10.3892/mmr.2013.1356. https://www.ncbi.nlm.nih.gov/pubmed/23467912